| Literature DB >> 35169045 |
Samantha D Creighton1,2, Kristen H Jardine1, Alexa Desimone1, Megan Zmetana1, Sabrina Castellano3, Ciro Milite3, Gianluca Sbardella3, Boyer D Winters1.
Abstract
Histone acetylation, catalyzed by histone acetyltransferases, has emerged as a promising therapeutic strategy in Alzheimer's disease (AD). By longitudinally characterizing spatial memory at 3, 6, and 9 mo of age, we show that acute activation and inhibition of the histone acetyltransferase PCAF remediated memory impairments in 3xTG-AD mice in an age-related bidirectional manner. At 3 and 6 mo of age, PCAF activation ameliorated memory deficits. At 9 mo of age, PCAF activation had no effect on spatial memory, whereas PCAF inhibition improved memory deficits in females. This work reveals a complex potential therapeutic role for PCAF in AD, initially benefitting memory but becoming detrimental as the disease progresses.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35169045 PMCID: PMC8852226 DOI: 10.1101/lm.053536.121
Source DB: PubMed Journal: Learn Mem ISSN: 1072-0502 Impact factor: 2.460